Treatment of Depression with SNRIs and TCAs

Efficacy Comparison

The American Academy of Family Physicians recommends SNRIs over TCAs for most patients with depression due to their superior safety and tolerability profile, while maintaining comparable efficacy 1, 2
SNRIs demonstrate slightly higher remission rates compared to SSRIs (49% vs 42%), although this difference is marginal 3
TCAs, such as clomipramine and amitriptiline, may show superior efficacy in severe depression and hospitalized patients 4

The American Academy of Family Physicians notes that TCAs cause significant anticholinergic effects, including dry mouth, urinary retention, constipation, blurred vision, cognitive impairment, confusion, and delirium, particularly in the elderly 1
SNRIs are essentially free of anticholinergic effects 1
TCAs have a higher risk of cardiovascular toxicity, with a risk of ventricular conduction abnormalities and ischemic heart disease, requiring ECG screening for patients over 40 years old and dosage limitation to <100 mg/day when possible 5

The American Academy of Family Physicians recommends starting with an SSRI for most patients with major depression, due to their equivalent efficacy but superior safety profile 4
SNRIs are preferred over TCAs as a second-line treatment, especially for patients with chronic pain comorbidity 3, 4
Duloxetine and venlafaxine are recommended as first-line treatments for neuropathic pain, with duloxetine preferred due to its superior safety profile 5

The American Geriatrics Society recommends avoiding TCA tertiary agents (amitriptiline, imipramine) in elderly patients due to their significant anticholinergic effects and risk of falls 1
Preferred agents for elderly patients include citalopram, escitalopram, sertraline, mirtazapine, and venlafaxine 1, 3
Patients with cardiac comorbidities should avoid TCAs and prefer duloxetine, which does not cause clinically significant cardiovascular changes 5

The American Academy of Family Physicians warns against prescribing TCAs without ECG screening in patients over 40 years old 5
Monitoring blood pressure is necessary when using venlafaxine 5
Treatment should not be discontinued too early, as it should last at least 4 months for a first episode of depression 1, 2, 3

The American Academy of Family Physicians recommends that treatment for a first episode of major depression should last at least 4-12 months after remission, regardless of the chosen medication class 1, 2, 4
Patients with recurrent depression may benefit from prolonged treatment with both SNRIs and TCAs 1, 3

Duloxetine provides the strongest analgesic benefit among SNRIs for older adults with chronic pain, supported by high‑quality evidence from two geriatric studies. 6, 7
Milnacipran is an alternative SNRI but has less robust analgesic evidence, making it a secondary option when duloxetine is unsuitable. 6, 7

SSRIs have the lowest analgesic effect of all antidepressant classes and are less effective at improving cognition compared with SNRIs, indicating a relative disadvantage for memory enhancement. (moderate strength of evidence) 8
Agents that increase norepinephrine (SNRIs, TCAs, mirtazapine) produce greater pain relief and may enhance cognitive function more than pure serotonergic SSRIs; the noradrenergic component is considered key to these cognitive benefits. (moderate strength) 8

Venlafaxine exhibits the minimal impact on the CYP450 enzyme system among SNRIs, thereby lowering the risk of drug‑drug interactions in polypharmacy‑prone older patients. (moderate strength) 9, 10

When chronic pain co‑exists with depression in older adults, clinicians should preferentially select an SNRI (e.g., duloxetine) to address both conditions effectively. (moderate strength) 8, 6, 7

Begin therapy with the lowest available dose of the chosen antidepressant, irrespective of class, to minimize adverse effects. (moderate strength) 6, 7
Increase the dose in small increments, observing the patient for at least one week at each step, to ensure tolerability and safety. (moderate strength) 6, 7

All antidepressants should be tapered slowly when discontinuing to reduce the likelihood of discontinuation syndrome. (moderate strength) 6, 7
SNRIs, in particular, require a gradual taper because they are associated with more pronounced withdrawal symptoms than other classes. (moderate strength) 9, 10
Abrupt cessation of any SNRI should be avoided due to the risk of withdrawal phenomena. (moderate strength) 6, 7, 9, 10

Concurrent use of SNRIs with monoamine oxidase inhibitors (MAOIs) must be avoided because of the potential for serotonin syndrome. (moderate strength) 9, 10